Respiratory quinolones in treatment of community-acquired pneumonia

1. Ноников В.Е. Атипичные пневмонии. Антибиотики и химиотер. 2001; 46 (6): 32-37.

2. Ноников В.Е. Антибактериальная терапия пневмоний в стационаре. Рус. мед. журн. 2001; 9 (21): 923-929.

3. Ноников В.Е. Дифференциальная диагностика и антибактериальная терапия пневмоний. Consilium M edicum 2001; 3 (12): 569-573.

4. Яковлев С.В., Мохов О.И. Моксифлоксацин — препарат нового поколения фторхинолонов для лечения инфекций дыхательных путей. Инфекции и антимикроб, тер. 2000; 2 (4): 104-109.

5. Bartlett J. Pocket book of infectious disease therapy. Philadelphia: Lippincott; Baltim ore: W illiam s & W ilkins; 2000.

6. Hautamak D., Bruya Т., Kurishi A. et at. Short-course (5-day) moxifloxacin versus 7-day levofloxacin therapy for treatment of acute exacerbation of chronic bronchitis. Today’s Ther. Trends 2001; 19 (2): 117-136.

7. Krasemann C., Meyer J., Tillotson G. Evaluation of the clinical microbiology profile of moxifloxacin. Clin. Infect. Dis. 2001; 32 (suppl. 1): 551-561.

8. Landen H., Moller М., Tillotson G. et at. Clinical experience in Germ any of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin. J. Intern. Med. Res. 2001; 29 (2): 51-60.

9. Landen H., Bauer T. Efficacy, onset of action and tolerability of moxifloxacin in patients with community-acquired pneumonia. Clin. Drug Invest. 2001; 21 (12): 801-811.

10. Petipretz P., Arvis P., Marel M. et al. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild to moderate, community-acquired. Suspected pneum ococcal pneumonia in adults. Chest 2001; 119: 185-195.